Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Company Overview

Xenon Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs. Its lead asset, XEN1101, is an orally administered potassium channel opener being evaluated for the treatment of focal epilepsy, while other programs target sodium and calcium channel modulators for migraine prophylaxis and pain management. Xenon has established strategic collaborations with academic institutions and contract research organizations to conduct global Phase 1 and Phase 2 studies, with trial sites spanning North America and Europe. Throughout its development efforts, the company leverages translational biomarkers and electrophysiology to guide clinical dosing and patient selection.

Founded in 1999 and headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals trades on the Nasdaq under the ticker XENE. Over its history, the company has transitioned from a technology licensee to a fully integrated drug developer, expanding its team of medicinal chemists, pharmacologists and clinical specialists. Xenon is led by President and Chief Executive Officer C. Scott Myers, whose experience in neuroscience drug development supports the company’s mission to advance therapies for patients with unmet medical needs worldwide.

Key Stats

• Today's Range: $62.43 to $64.31
• 50-Day Range: $51.21 to $70.96
• 52-Week Range: $32.78 to $72.66
• Volume: 639,257 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $6.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $77.20
• Consensus Rating: Buy

Xenon Pharmaceuticals Stock Analysis - MarketRank™

Xenon Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 304th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Xenon Pharmaceuticals has a consensus price target of $77.20, representing about 20.6% upside from its current price of $64.01.

Amount of Analyst Coverage

Xenon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.92) to ($5.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xenon Pharmaceuticals is -13.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xenon Pharmaceuticals is -13.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xenon Pharmaceuticals has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.75% of the float of Xenon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xenon Pharmaceuticals has recently increased by 1.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xenon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Xenon Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.33

News Sentiment

Xenon Pharmaceuticals has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Xenon Pharmaceuticals this week, compared to 6 articles on an average week.

MarketBeat Follows

Only 1 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $133,488.00 in company stock.

Percentage Held by Insiders

2.91% of the stock of Xenon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/04/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XENE
• CIK: 1582313
• Web: www.xenon-pharma.com
• Phone: (604) 484-3300
• Fax: 604-484-3450
• Employees: 210
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Xenon Pharmaceuticals: $77.20
• High Price Target: $100.00
• Low Price Target: $55.00
• Potential Upside/Downside: +20.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$345.91 million
• Net Margins: N/A
• Pretax Margin: -4,598.59%
• Return on Equity: -49.23%
• Return on Assets: -46.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.79
• Quick Ratio: 27.79

Sales & Book Value

• Annual Sales: $7.50 million
• Price / Sales: 825.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.53 per share
• Price / Book: 8.50

Miscellaneous

• Outstanding Shares: 96,670,000
• Free Float: 93,853,000
• Market Cap: $6.19 billion
• Optionable: Optionable
• Beta: 0.62